Urologic disease

MDxHealth Reports Q3-2022 Results

Retrieved on: 
Thursday, October 27, 2022

Excluding the Oncotype DX GPS revenues, total revenues were $20.8 million, an increase of 28% compared to the first nine months of 2021.

Key Points: 
  • Excluding the Oncotype DX GPS revenues, total revenues were $20.8 million, an increase of 28% compared to the first nine months of 2021.
  • Gross profit for the three months ended September 30, 2022, was $6.2 million, an increase of 143% as compared to $2.6 million for the three months ended September 30, 2021.
  • Mr. McGarrity concluded, Todays results reflect our previously communicated view that mdxhealth is fast becoming a leading precision diagnostics company that can deliver sustainable growth.
  • Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment.

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

Retrieved on: 
Tuesday, October 11, 2022

The deal grants NBP Pharma the exclusive rights to develop and commercialize batoclimab in Greater China including mainland of China, HongKong, Macau,and Taiwan.

Key Points: 
  • The deal grants NBP Pharma the exclusive rights to develop and commercialize batoclimab in Greater China including mainland of China, HongKong, Macau,and Taiwan.
  • "We are pleased to have reached this agreement with Harbour BioMed," said Cuilong Zhang, CEO of CSPC through the press release by Harbour BioMed.
  • "Batoclimab is a promising innovative drug, and we hope to accelerate its clinical development, manufacturing, registration and commercialization in China, so as to benefit the patients in China better and earlier,"he added.
  • "HanAll welcomes CSPC to join our journey to develop innovative medicines for patients in China.

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

Retrieved on: 
Tuesday, October 4, 2022

Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402)

Key Points: 
  • Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402)
    Batoclimab (formerly known as HL161BKN) and HL161ANS originated from HanAll.
  • Both batoclimab and HL161ANS compounds were licensed to Roivant Sciences in regions including North America, South America, and Europe in 2017.
  • HL161ANS demonstrated deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein in animal studies.
  • "We are excited with the potential contribution our second FcRn inhibitor HL161ANS can make to patients suffering from severe autoimmune diseases," said Sean Jeong, M.D., CEO of HanAll Biopharma.

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

Retrieved on: 
Wednesday, August 10, 2022

SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a global biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other related diseases, announces Dr. Badrinath Konety has joined Asieris' Scientific Advisory Board as an advisor.

Key Points: 
  • SHANGHAI, Aug. 10, 2022 /PRNewswire/ --Asieris Pharmaceuticals (stock code: 688176.SH), a global biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other related diseases, announces Dr. Badrinath Konety has joined Asieris'Scientific Advisory Board as an advisor.
  • Dr. Konety has more than 30 years of clinical research and medical practice experience in the field of genitourinary oncology.
  • "We are honored to have Dr. Konety in our Scientific Advisory Board," remarked Dr. Kevin Pan, Founder and CEO of Asieris.
  • "I'm impressed by Asieris' global vision as well as its innovative pipeline powered by its competitive research and development engine," Dr. Konety stated.

Global Nanomedicine Market (2022 to 2027) - Players Include Abbott, Arrowhead Research, Bio-gate and Celgene - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022

The Global Nanomedicine Market is estimated to be USD 194.14 Mn in 2022 and is projected to reach USD 359.91 Mn by 2027, growing at a CAGR of 13.14%.

Key Points: 
  • The Global Nanomedicine Market is estimated to be USD 194.14 Mn in 2022 and is projected to reach USD 359.91 Mn by 2027, growing at a CAGR of 13.14%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Nanomedicine Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Nanomedicine Market.
  • The report analyses the Global Nanomedicine Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Endoluxe Enters Into Multi-year USA Distribution Agreement With Dornier MedTech for Urology Segment

Retrieved on: 
Thursday, June 9, 2022

Endoluxe is pleased to announce that they have entered into a multi-year exclusive distribution agreement specifically for the urology market with Dornier MedTech.

Key Points: 
  • Endoluxe is pleased to announce that they have entered into a multi-year exclusive distribution agreement specifically for the urology market with Dornier MedTech.
  • Dornier and Endoluxe have products and platforms focused in the urology arena offering innovation and value.
  • We are absolutely ecstatic to partner with Dornier MedTech to address the growing demands for better imaging solutions in urology, states CEO Devon Bream.
  • With the various new urology products that Dornier introduced at AUA, it is an ideal situation to have Endoluxe join our portfolio of market leading urology products, states Brock Faulkner, CEO of Dornier MedTech America.

May is Women's Health Month

Retrieved on: 
Monday, May 2, 2022

BALTIMORE, May 2, 2022 /PRNewswire/ -- May marks the start of Women's Health Month, a time dedicated to the health and wellness of women throughout the world. The Urology Care Foundation, the official Foundation of the American Urological Association and the world's leading nonprofit urological health foundation, utilizes the month of May to educate and raise awareness of urology-related conditions and diseases that affect women, such as overactive bladder, urinary tract infections, incontinence, interstitial cystitis and bladder cancer.

Key Points: 
  • BALTIMORE, May 2, 2022 /PRNewswire/ -- May marks the start of Women's Health Month, a time dedicated to the health and wellness of women throughout the world.
  • "Women's Health Month reminds women to take control of their own health," said Harris M. Nagler, MD, president of the Urology Care Foundation.
  • "The Urology Care Foundation serves as a source of trusted resources to help empower women to improve their urologic health, and therefore, their overall health.
  • About the Urology Care Foundation:The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

Retrieved on: 
Tuesday, March 22, 2022

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.

Key Points: 
  • FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.
  • Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (Nasdaq: URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease.
  • Molly brings to Phathom deep financialacumenand significant industry experience across mid-size and large-scalecommercialorganizations, and we are excited to have her join our executive leadership team, said Terrie Curran, President and Chief Executive Officer of Phathom.
  • She was previously the Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Ms. Henderson holds an MBA and MS in Accounting from the State University of New York at Buffalo.

UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022

Retrieved on: 
Friday, March 4, 2022

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market.
  • The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer

Retrieved on: 
Monday, February 21, 2022

SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS)announced today the appointment of Almira Chabi, M.D.

Key Points: 
  • SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS)announced today the appointment of Almira Chabi, M.D.
  • as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengthen its R&D capability.
  • "We are extremely pleased to welcome Dr. Chabi as Chief Medical and Development Officer.
  • "I highly value the potential and commitment of HanAll Biopharma to provide innovative therapies that serve patients' needs," Dr. Chabi stated.